


# **Neuromyelitis Optica**

# 1

## Annual number of neuromyelitis optica patients

**Index definition** Annual number of patients treated for neuromyelitis optica (NMO) according to the guideline to diagnose rare and incurable diseases

**Description** The number of diagnoses and treatments for NMO patients is increasing each year.



### Calculation

#### Numerator

Number of patients treated for NMO for the year

① Diagnosis name: NMOSD


② Department: Neurology

## 2

# Proportion of anti-CD20 (rituximab) treatments for neurocyclitis optica

**Index definition** Proportion of anti-CD20 (rituximab) treatments for NMO patients

**Description** The number of anti-CD20 (rituximab) treatments for NMO is increasing each year, but the proportion of the treatment is at similar levels.



### Calculation

**Numerator** Patients who received anti-CD20 (rituximab) treatment

**Denominator** Number of patients treated for NMO

① Diagnosis name: NMOSD

② Department: Neurology


# 3

## Proportion of plasmapheresis treatments for neurocyelitis optica

**Index definition** Proportion of plasmapheresis treatments for NMO patients

**Description** SNUH additionally performs plasmapheresis treatment for NMO patients when there is an insufficient response to acute corticosteroid therapy. The proportion of the treatment fluctuates every year depending on the severity of the patient group.

(Unit: %)



**Calculation**

**Numerator** Patients who received plasmapheresis treatment

**Denominator** Number of patients treated for NMO

① Diagnosis name: NMOSD

② Department: Neurology